Видео ютуба по тегу Lexeo Therapeutics

Lexeo Therapeutics Positive Interim Phase I II Data for LX2020 for the Treatment of PKP2 Associated
Lexeo Therapeutics Positive Interim Phase I II Data for LX2020 for the Treatment of PKP2 Associated
Accelerating Development Through Regulatory Flexibility: Evolving Endpoints in Gene Therapy
Accelerating Development Through Regulatory Flexibility: Evolving Endpoints in Gene Therapy
Lexeo Therapeutics A Clinician’s Perspective: Holistic Approach to Managing PKP2 Associated Arrhythm
Lexeo Therapeutics A Clinician’s Perspective: Holistic Approach to Managing PKP2 Associated Arrhythm
Living with Friedreich Ataxia: The Van Och Family
Living with Friedreich Ataxia: The Van Och Family
PRICE RECOVERY : LXEO STOCK ANALYSIS | LEXEO THERAPEUTICS INC STOCK
PRICE RECOVERY : LXEO STOCK ANALYSIS | LEXEO THERAPEUTICS INC STOCK
EP 173: Tackling genetic cardiomyopathy from the bed to the bench with Eric Adler of Lexeo Therap...
EP 173: Tackling genetic cardiomyopathy from the bed to the bench with Eric Adler of Lexeo Therap...
Living with Friedreich Ataxia: Aly's Story
Living with Friedreich Ataxia: Aly's Story
LEXEO THERAPEUTICS INC 2025 quarterly report
LEXEO THERAPEUTICS INC 2025 quarterly report
Trending in Gene & Cell Therapy: Intellia pause, Adverum M&A and more
Trending in Gene & Cell Therapy: Intellia pause, Adverum M&A and more
Trending in Gene & Cell Therapy: Intellia pause, Adverum M&A and more
Trending in Gene & Cell Therapy: Intellia pause, Adverum M&A and more
FA Symposium 2025: Friedreich's Ataxia Drug Development Pipeline Update and Q&A (Session #7)
FA Symposium 2025: Friedreich's Ataxia Drug Development Pipeline Update and Q&A (Session #7)
Trending in Gene & Cell Therapy: Intellia pause, Adverum M&A and more
Trending in Gene & Cell Therapy: Intellia pause, Adverum M&A and more
Gene & Cell Therapy Update – October 30, 2025: Intellia pause, Lilly–Adverum deal and More
Gene & Cell Therapy Update – October 30, 2025: Intellia pause, Lilly–Adverum deal and More
At the Heart of Gene Therapy: Lexeo’s R. Nolan Townsend on Genetic Medicines
At the Heart of Gene Therapy: Lexeo’s R. Nolan Townsend on Genetic Medicines
Beyond Traditional Drugs Novel Platforms Targeting Hard to Treat Conditions
Beyond Traditional Drugs Novel Platforms Targeting Hard to Treat Conditions
Lexeo Therapeutics Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim
Lexeo Therapeutics Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim
Living with Friedreich Ataxia
Living with Friedreich Ataxia
LXEO Stock Analysis (Lexeo Therapeutics Stock) October 7, 2025
LXEO Stock Analysis (Lexeo Therapeutics Stock) October 7, 2025
The BioHub - The Avetix Podcast - S2 Ep69 - Nolan Townsend - CEO of Lexeo Therapeutics
The BioHub - The Avetix Podcast - S2 Ep69 - Nolan Townsend - CEO of Lexeo Therapeutics
NEXT BIG BREAKOUT : LXEO STOCK ANALYSIS | LEXEO THERAPEUTICS INC STOCK
NEXT BIG BREAKOUT : LXEO STOCK ANALYSIS | LEXEO THERAPEUTICS INC STOCK
Gene Therapy in PKP2 ACM Clinical Trials
Gene Therapy in PKP2 ACM Clinical Trials
Gene Therapy Restores Hearing, CAR-T Advances, Diabetes Trials & More
Gene Therapy Restores Hearing, CAR-T Advances, Diabetes Trials & More
Gene Therapy Restores Hearing, CAR-T Advances, Diabetes Trials & More
Gene Therapy Restores Hearing, CAR-T Advances, Diabetes Trials & More
Gene Therapy Restores Hearing, CAR-T Advances, Diabetes Trials & More
Gene Therapy Restores Hearing, CAR-T Advances, Diabetes Trials & More
Gene Therapy Restores Hearing, CAR-T Advances, Diabetes Trials & More
Gene Therapy Restores Hearing, CAR-T Advances, Diabetes Trials & More